Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue (90)Y-[DOTA](0)-Tyr(3)-octreotide [(90)Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.
Bodei
Lisa
L
Nuclear Medicine Division, European Institute of Oncology, Milan, Italy.
Cremonesi
Marta
M
Grana
Chiara
C
Rocca
Paola
P
Bartolomei
Mirco
M
Chinol
Marco
M
Paganelli
Giovanni
G
D000818:Animals; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011832:Radiation Injuries / Q000209:etiology; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods* / Q000639:trends*; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D015282:Octreotide; C106246:Edotreotide